Navigation Links
ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
Date:7/29/2009

SCOTTSDALE, Ariz., July 29 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.

Preliminary analysis of ongoing bioavailability studies in rats had revealed the oral administration of Homspera resulted in measurable amounts of the drug in lung tissue. Systemic absorption and accumulation in lungs was found after both oral and intra-duodenal administration in studies performed by a major, global contract research organization, with analytical work performed at MDx Bioanalytical Inc. of Tucson, Arizona.

Based on these findings, the Company commissioned H1N1 virus studies to be performed in the laboratories of a widely-respected University scientist. Using the accepted ferret model of H1N1 influenza virus infection, animals were treated orally (initially) with Homspera starting 24 hours following infection. While data collection and analysis is ongoing, preliminary evaluation of temperatures of infected ferrets reveals that orally-administered Homspera lessened the impact of influenza infection, resulting in shortened duration and more rapid resolution of the hyperthermia associated with infection.

Immune markers of infection remain to be assessed, but this pilot study apparently reveals that the ability of Homspera to attenuate symptoms of influenza virus infection, which have previously been reported in cotton rats infected with H3N2 influenza and in ferrets infected with H5N1 influenza, also extends to the current pandemic H1N1 strain.

These results, although preliminary, support the hypoth
'/>"/>

SOURCE ImmuneRegen BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
2. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
3. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... Calif. , Aug. 20, 2014 /PRNewswire-iReach/ -- ... the transformative collaboration between the school,s bioengineering department ... part of the Intel® Software Academic Program, UCSD,s ... sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/20/2014)... 2014 WriteResult®, a leading provider of ... has expanded its myPROpad™ ePRO tablet with the addition ... of the most widely used and well-respected Patient Reported ... The EQ-5D is used during clinical trials and in ... can be used to demonstrate Health-Related Quality of Life ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... (NYSE Amex: CUR ) announced that the ongoing ... in amyotrophic lateral sclerosis (ALS or Lou Gehrig,s disease) was ... http://www.neuralstem.com/neuralstem-in-the-news (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) The trial ... injections. About Neuralstem ...
... N.J., Nov. 13, 2011 Pharmasset, Inc. (Nasdaq: ... Capital Markets 8th Annual Healthcare Conference to be held November ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will provide ... 3:00 PM (ET). To access a simultaneous webcast ...
... Discharge 1-2-3 of Schaumburg, IL has been ... Innovation Awards for their Discharge 1-2-3 Composer™. The ... Theater on Tuesday, November 8, with more than 1400 people ... the Chicago region,s foremost recognition of the most innovative new ...
Cached Biology Technology:Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 3Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 2Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 3
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
(Date:8/20/2014)... Research UK scientists have discovered that acral melanomas the ... Marley,s death are genetically distinct from other more common ... external) published in the journal Pigment Cell & Melanoma ... of the hands, soles of the feet, nail-beds and other ... of melanoma, it,s not caused by UV damage from the ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2
... Leuven, Belgium - When a blood vessel clogs up, a ... die. However, working with mice, VIB scientists connected to the ... with severe hypoxia from dying. The muscles seem to adapt ... force that animals also use when hibernating, but that has ...
... critical difference between flu viruses that infect birds and humans, ... avian flu strains and aid in the development of vaccines ... a virus,s ability to infect humans depends on whether it ... surface of human respiratory cells. Now that we know ...
... in marine biomedical laboratories at Scripps Institution of Oceanography ... information about the fundamental biological processes inside a marine ... to treat cancer in humans. The finding could lead ... human diseases. A research team led by Bradley ...
Cached Biology News:Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers 2MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3Researchers uncover key trigger for potent cancer-fighting marine product 2
Rac 1/2/3/4 (S-18)...
... Recognizes K+ Cl- ... shows no significant sequence ... or CCC.,SPECIES REACTIVITIES: The ... conserved in human, mouse, ...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Biology Products: